118 related articles for article (PubMed ID: 37717784)
1. Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Long-Term Results From the PKUFH Randomized Phase 3 Trial.
Li HZ; Qi X; Gao XS; Li XM; Qin SB; Li XY; Ma MW; Bai Y; Chen JY; Ren XY; Li XY; Wang D
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):697-705. PubMed ID: 37717784
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and Biochemical Outcomes of Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Results of a Randomized Phase III Trial.
Qi X; Li HZ; Gao XS; Qin SB; Zhang M; Li XM; Li XY; Ma MW; Bai Y; Li XY; Wang D
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):282-290. PubMed ID: 31669564
[TBL] [Abstract][Full Text] [Related]
3. Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens.
Tandberg DJ; Oyekunle T; Lee WR; Wu Y; Salama JK; Koontz BF
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):396-405. PubMed ID: 29559284
[TBL] [Abstract][Full Text] [Related]
4. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H
JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933
[TBL] [Abstract][Full Text] [Related]
5. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
[TBL] [Abstract][Full Text] [Related]
6. External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume.
Tharmalingam H; Tsang Y; Choudhury A; Alonzi R; Wylie J; Ahmed I; Henry A; Heath C; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):525-533. PubMed ID: 31610249
[TBL] [Abstract][Full Text] [Related]
7. Salvage radiation therapy after radical prostatectomy: survival analysis.
Galla A; Maggio A; Delmastro E; Garibaldi E; Gabriele P; Bresciani S; Di Dia A; Stasi M; Gabriele D
Minerva Urol Nefrol; 2019 Jun; 71(3):240-248. PubMed ID: 30037205
[TBL] [Abstract][Full Text] [Related]
8. 20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial.
Merrick GS; Wallner KE; Butler WM; Galbreath RW; Taira AV; Orio P; Adamovich E
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e449-55. PubMed ID: 22196131
[TBL] [Abstract][Full Text] [Related]
9. Assessing radiation dose for postoperative radiotherapy in prostate cancer: Real world data.
Hervás-Morón A; Domínguez-Rullán J; Santana VD; Valero M; Vallejo C; Sancho S; Fuentes JDG; López-Campos F; Gallego MC
World J Clin Oncol; 2022 Jul; 13(7):652-662. PubMed ID: 36157159
[TBL] [Abstract][Full Text] [Related]
10. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288
[TBL] [Abstract][Full Text] [Related]
12. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
13. Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.
Matzkin H; Chen J; Agai R; Ziv-Baran T; Mabjeesh NJ
PLoS One; 2019; 14(4):e0215582. PubMed ID: 31002732
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy after radical prostatectomy for adenocarcinoma of the prostate: a UK institutional experience and review of published studies.
Hudson E; Kynaston H; Varma M; Carter A; Staffurth J; Barber J; Mason MD; Lester JF
Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):353-7. PubMed ID: 18407476
[TBL] [Abstract][Full Text] [Related]
15. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
16. Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy.
Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Hamstra DA
Am J Clin Oncol; 2016 Apr; 39(2):181-8. PubMed ID: 24517957
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
18. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
Parker CC; Clarke NW; Cook AD; Kynaston HG; Petersen PM; Catton C; Cross W; Logue J; Parulekar W; Payne H; Persad R; Pickering H; Saad F; Anderson J; Bahl A; Bottomley D; Brasso K; Chahal R; Cooke PW; Eddy B; Gibbs S; Goh C; Gujral S; Heath C; Henderson A; Jaganathan R; Jakobsen H; James ND; Kanaga Sundaram S; Lees K; Lester J; Lindberg H; Money-Kyrle J; Morris S; O'Sullivan J; Ostler P; Owen L; Patel P; Pope A; Popert R; Raman R; Røder MA; Sayers I; Simms M; Wilson J; Zarkar A; Parmar MKB; Sydes MR
Lancet; 2020 Oct; 396(10260):1413-1421. PubMed ID: 33002429
[TBL] [Abstract][Full Text] [Related]
19. Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.
Ghadjar P; Hayoz S; Bernhard J; Zwahlen DR; Hölscher T; Gut P; Polat B; Hildebrandt G; Müller AC; Plasswilm L; Papachristofilou A; Schär C; Sumila M; Zaugg K; Guckenberger M; Ost P; Reuter C; Bosetti DG; Khanfir K; Gomez S; Wust P; Thalmann GN; Aebersold DM;
Eur Urol; 2021 Sep; 80(3):306-315. PubMed ID: 34140144
[TBL] [Abstract][Full Text] [Related]
20. Salvage Whole-Pelvic Radiation and Long-Term Androgen-Deprivation Therapy in the Management of High-Risk Prostate Cancer: Long-Term Update of the McGill 0913 Study.
Elakshar S; Tolba M; Tisseverasinghe S; Pruneau L; Di Lalla V; Bahoric B; Niazi T
Curr Oncol; 2023 Aug; 30(8):7252-7262. PubMed ID: 37623007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
